Abstract—Contemporarily, human beings live in an uneasy time with global economic and financial unrest, especially stirred by the COVID-19. Health and wellness are more important than ever; hence pharmaceutical companies have become an attractive investment target. We selected key statistics from the balance sheet, income statement, and cash flow statement to evaluate and compare major pharmaceutical companies' valuation, growth, profitability, and payout, based on the DDM model. These companies include GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, MERCK & Co, Amgen Inc, Bristol Myers Squibb Co, Pfizer Inc, and Novo Nordisk A/S. According to the calculation of ratios and the comparison of growth rates and profitability to other selected pharmaceutical companies, GlaxoSmithKline is the best investment target among the eight companies in the comparison list. Specifically, GlaxoSmithKline has both P/E and EV/Sales ratios ranked the lowest in 2020; both average sales growth and average EPS growth rates are ranked at 2nd, average EBITDA growth ranked at 5th for the financial year###-###-#### The GP/A ratio for GlaxoSmithKline is above the list's average. In a broad sense, there is still an opportunity for growth in medical company equities as the epidemic continues. In particular, we need to choose a firm that has a stable and sustainable growth rate, advanced medical technology, and a suitable and mature system. Our pharmaceutical equity research can lend more insight to other researchers or investors interested in healthcare stocks.